Skip to main content
. 2017 Feb 24;8(20):32769–32782. doi: 10.18632/oncotarget.15680

Table 1. Correlation between SerpinB2 overexpression and BC clinical parameters.

Parameters No. of cases SerpinB2-high (%) SerpinB2-low (%) P-value
Breast cancer 337 216(64.1) 121(35.9)
Age
 ≧50 235 156(66.4) 79(33.6) 0.184
 <50 102 60(58.8) 42(41.2)
Tumor size
 ≧2cm 237 164(69.2) 73(30.8) 0.002
 <2cm 100 52(52.0) 48(48.0)
TNM stage
 I-II 229 133(58.1) 96(41.9) 0.000
 III-IV 108 83(76.9) 25(23.1)
Histology grade
 Well 59 34(57.6) 25(42.4) 0.129
 Moderate 206 129(62.6) 77(37.4)
 Poor 72 53(73.6) 19(26.4)
LN metastasis
 Negative 189 105(55.6) 84(44.4) 0.000
 Positive 148 111(75.0) 37(25.0)
ER
 Negative 144 97(67.4) 47(32.6) 0.2803
 Positive 193 119(61.7) 74(38.3)
PR
 Negative 170 111(65.3) 59(34.7) 0.643
 Positive 167 105(62.9) 62(37.1)
HER2
 Negative 192 125(65.1) 67(34.9) 0.657
 Positive 145 91(62.8) 54(37.2)

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal receptor 2.